Amoxapine

Sold as Asendin. Every FDA application for this active ingredient: 1 branded and 6 generic.

As of Nov 15, 2026, FDA lists 7 applications for Amoxapine (sold as Asendin), first approved Sep 22, 1980, with 0 new uses approved and 0 published complete response letters.

First approved: Sep 22, 1980
Applications: 7
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $188K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Amoxapine	Part D	$188K	+1%	401

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Sep 22, 1980	AsendinNDA 18021 · New molecular entity	Lederle	36	Discontinued
May 11, 1989	AmoxapineANDA 72418	Watson Pharms Teva	14	Discontinued
May 11, 1989	AmoxapineANDA 72419	Watson Pharms Teva	14	Discontinued
May 11, 1989	AmoxapineANDA 72420	Watson Pharms Teva	14	Discontinued
May 11, 1989	AmoxapineANDA 72421	Watson Pharms Teva	14	Discontinued
Jun 28, 1991	AmoxapineANDA 72879	Chartwell Rx	11	Marketed
Aug 28, 1992	AmoxapineANDA 72691	Watson Labs	13	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA